Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

NCT06247826 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT06247826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Not applicable
Overall status
Recruiting
Start date
January 15, 2024
Completion date
July 30, 2026
Enrollment
30 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 20 insertion mutation, non-small cell lung cancer